Vascular permeability factors in steroid-sensitive nephrotic syndrome and focal segmental glomerulosclerosis

Nephrology Dialysis Transplantation

Volumn 18, Issue SUPPL. 6, 2003, Pages

  Brenchley, Paul E C ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Focal; Haemopexin; Heparanase; Pathogenesis; Segmental glomerulosclerosis; Steroid sensitive nephrotic syndrome; Vascular permeability factor; VEGF

Indexed keywords

HEPARANASE; IMMUNOSUPPRESSIVE AGENT; STEROID; VASCULOTROPIN;

CAPILLARY WALL; DRUG SENSITIVITY; EVIDENCE BASED MEDICINE; FOCAL GLOMERULOSCLEROSIS; GENETIC POLYMORPHISM; GLOMERULUS CAPILLARY; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; LYMPHOCYTE; NEPHROTIC SYNDROME; NONHUMAN; PLASMA FACTOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN ISOLATION; PROTEINURIA; REVIEW;

GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; NEPHROTIC SYNDROME; STEROIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0012853213     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Broyer M, Meyrier A, Niaudet P, Habib R. Minimal changes and focal segmental sclerosis. In: Oxford Textbook of Clinical Nephrology, 2nd ed. Vol. 1, 1998
2. Mauer SM, Hellerstein S, Cohn RA, Sibley RK, Vernier RL. Recurrence of steroid-responsive nephrotic syndrome after renal transplantation. J Pediatr 1979; 95: 261-264
3. Ali AA, Wilson E, Moorhead JF et al. Minimal-change glomerular nephritis. Normal kidneys in an abnormal environment? Transplantation 1994; 58: 849-852
4. Shaloub RJ. Pathogenesis of lipoid nephrosis: a disorder of T cell function. Lancet 1974; 2: 556-560
5. Lagrue G, Xheneumont S, Branellec A, Hirbec G, Weil B. A vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome. Biomedicine 1975; 23: 37-40
6. Lagrue G, Branellec A, Blanc C et al. A vascular permeability factor in lymphocyte culture supernatants from patients with nephrotic syndrome. II. Pharmacological and physicochemical properties. Biomedicine 1975; 23: 73-75
7. Pick E, Krejci J, Cech J, Turk J. Interaction between sensitised lymphocytes and antigen in vitro. I. The release of a skin reactive factor. Immunology 1969; 17: 741
8. Heslan JM, Branellec A, Laurent J, Lagrue G. The vascular permeability factor is a T lymphocyte product. Nephron 1986; 42: 187-188
9. Heslan JM, Branellec AI, Pilatte Y, Lang P, Lagrue G. Differentiation between vascular permeability factor and IL-2 in lymphocyte supernatants from patients with minimal-change nephrotic syndrome. Clin Exp Immunol 1991; 86: 157-162
10. Tomizawa S, Maruyama K, Nagasawa N, Suzuki S, Kuroume T. Studies of vascular permeability factor derived from T lymphocytes and inhibitory effect of plasma on its production in minimal change nephrotic syndrome. Nephron 1985; 41: 157-160
11. Maruyama K, Tomizawa S, Seki Y, Arai H, Kuroume T. Inhibition of vascular permeability factor production by ciclosporin in minimal change nephrotic syndrome. Nephron 1992; 62: 27-30
12. Matsumoto K. Interleukin 10 inhibits vascular permeability factor release by peripheral blood mononuclear cells in patients with lipoid nephrosis. Nephron 1997; 75: 154-159
13. Matsumoto K, Ohi H, Kanmatsuse K. Interleukin 12 upregulates the release of vascular permeability factor by peripheral blood mononuclear cells from patients with lipoid nephrosis. Nephron 1998; 78: 403-409
14. Matsumoto K, Ohi H, Kanmatsuse K. Effects of interleukin-15 on vascular permeability factor release by peripheral blood mononuclear cells in normal subjects and in patients with minimal-change nephrotic syndrome. Nephron 1999; 82: 32-38
15. Matsumoto K, Ohi H, Kanmatsuse K. Interleukin-4 cooperates with interleukin-10 to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with minimal-change nephrotic syndrome. Am J Nephrol 1999; 19: 21-27
16. Matsumoto K, Ohi H, Kanmatsuse K. Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. Nephron 1997; 77: 212-218
17. Yoshizawa N, Kusumi Y, Matsumoto K et al. Studies of a glomerular permeability factor in patients with minimal-change nephrotic syndrome. Nephron 1989; 51: 370-376
18. Bakker WW, Beukhof JR, van LWH, van der HGK. Vascular permeability increasing factor (VPF) in IgA nephropathy. Clin Nephrol 1982; 18: 165-167
19. Bakker WW, van der LSM, Vos JT, Hoedemaeker PJ. The glomerular polyanion (GPA) of the rat kidney. I. Concanavalin-A activated cells affect the glomerular polyanion in vitro. Nephron 1982; 31: 68-74
20. Bakker WW, van LWH, Hene RJ, Desmit EM, van der HGK, Vos JT. Loss of glomerular polyanion in vitro induced by mononuclear blood cells from patients with minimal-change nephrotic syndrome. Am J Nephrol 1986; 6: 107-111
21. Boulton-Jones JM, Tulloch I, Dore B, McLay A. Changes in the glomerular capillary wall induced by lymphocyte products and serum of nephrotic patients. Clin Nephrol 1983; 20: 72-77
22. Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 1991; 40: 453-460
23. Bakker WW, Baller JF, van LWH. A kallikrein-like molecule and plasma vasoactivity in minimal change disease. Increased turnover in relapse versus remission. Contrib Nephrol 1988; 67: 31-36
24. Cheung PK, Klok PA, Bakker WW. Minimal change-like glomerular alterations induced by a human plasma factor. Nephron 1996; 74: 586-593
25. Cheung PK, Stulp B, Immenschuh S, Borghuis T, Baller JF, Bakker WW. Is 100KF an isoform of hemopexin? Immunochemical characterization of the vasoactive plasma factor 100KF. J Am Soc Nephrol 1999; 10: 1700-1708
26. Cheung PK, Klok PA, Baller JF, Bakker WW. Induction of experimental proteinuria in vivo following infusion of human plasma hemopexin. Kidney Int 2000; 57: 1512-1520
27. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999; 237: 97-132
28. Bottomley MJ, Webb NJ, Watson CJ, Holt PJ, Freemont AJ, Brenchley PE. Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid. Clin Exp Immunol 1999; 117: 171-176
29. Brenchley PEC. VPF/VEGF: a modulator of microvascular function with potential roles in glomerular pathophysiology. J Nephrol 1996; 9: 1-8
30. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995; 108: 2369-2379
31. Roberts WG, Palade GE. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 1997; 57: 765-772
32. Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, Risau W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 1998; 140: 947-959
33. Hippenstiel S, Krull M, Ikemann A, Risau W, Clauss M, Suttorp N. VEGF induces hyperpermeability by a direct action on endothelial cells. Am J Physiol Lung Cell Mol Physiol 1998; 18: L678-684
34. Chang YS, Munn LL, Hillsley MV et al. Effect of vascular endothelial growth factor on cultured endothelial cell monolayer transport properties. Microvasc Res 2000; 59: 265-277
35. Iijima K, Yoshikawa N, Connolly D, Nakamura H. Expression of vascular permeability factor by mesangial cells. J Am Soc Nephrol 1992; 3: 514a
36. Webb NJ, Watson CJ, Roberts IS et al. Circulating vascular endothelial growth factor is not increased during relapses of steroid-sensitive nephrotic syndrome. Kidney Int 1999; 55: 1063-1071
37. Klanke B, Simon M, Rockl W, Weich HA, Stolte H, Grone HJ. Effects of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) on haemodynamics and permselectivity of the isolated perfused rat kidney. Nephrol Dial Transplant 1998; 13: 875-885
38. Watson CJ, Webb NJA, Bottomley MJ, Brenchley PEC. Identification of polymorphisms within the vascular endothelial growth factor gene: correlation with variation in VEGF protein production. Cytokine 2000; 12: 1232-1235
39. Horita Y, Miyazaki M, Koji T et al. Expression of vascular endothelial growth factor and its receptors in rats with protein-overload nephrosis. Nephrol Dial Transplant 1998; 13: 2519-2528
40. Bailey E, Bottomley MJ, Westwell S et al. Vascular endothelial growth factor mRNA expression in minimal change, membranous and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation. J Clin Pathol 1999; 52: 735-738
41. Sewell RF, Brenchley PE, Mallick NP. Human mononuclear cells contain an endoglycosidase specific for heparan sulphate glycosaminoglycan demonstrable with the use of a specific solid-phase metabolically radiolabelled substrate. Biochem J 1989; 264: 777-783
42. Sewell RF, Short CD. Minimal-change nephropathy: how does the immune system affect the glomerulus? Nephrol Dial Transplant 1993; 8: 108-112
43. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nature Med 1999; 5: 803-809
44. Vlodavsky I, Friedmann Y, Elkin M et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nature Med 1999; 5: 793-802
45. Lewis EJ. Recurrent focal sclerosis after renal transplantation. Kidney Int 1982; 22: 315-323
46. Senggutuvan P, Cameron JS, Hartley RB et al. Recurrence of focal segmental glomerulosclerosis in transplanted kidneys: analysis of incidence and risk factors in 59 allografts. Pediatr Nephrol 1990; 4: 21-28
47. Dantal J, Baatard R, Hourmant M, Cantarovich D, Buzelin F, Soulillou JP. Recurrent nephrotic syndrome following renal transplantation in patients with focal glomerulosclerosis. A one-center study of plasma exchange effects. Transplantation 1991; 52: 827-831
48. Artero ML, Sharma R, Savin VJ, Vincenti F. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 1994; 23: 574-581
49. Dantal J, Bigot E, Bogers W et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994; 330: 7-14
50. Dantal J, Godfrin Y, Koll R et al Antihuman immunoglobulin affinity immunoadsorption decreases proteinuria in patients with relapsing nephrotic syndrome. J Am Soc Nephrol 1998; 9: 1709-1715
51. Godfrin Y, Dantal J, Perretto S et al. Study of the in vitro effect on glomerular albumin permselectivity of serum before and after renal transplantation in focal segmental glomerulosclerosis. Transplantation 1997; 64: 1711-1715
52. Sharma M, Sharma R, McCarthy ET, Savin VJ. 'The FSGS factor': enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. J Am Soc Nephrol 1999; 10: 552-561
53. Savin VJ, Sharma R, Lovell HB, Welling DJ. Measurement of albumin reflection coefficient with isolated rat glomeruli. J Am Soc Nephrol 1992; 3: 1260-1269
54. Savin VJ, Sharma R, Sharma M et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996; 334: 878-883